drug

Twinrix

MeSH C433226
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Dartmouth-Hitchcock Medical Center
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
NCT00316303Phase 2Completed

KOLs & investigators

2
Lisa B Dixon, MD, MPHKOL score 5
Stanley D. Rosenberg, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Dartmouth-Hitchcock Medical Center
company
trial
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
PHASE2
trial
indication
Schizophrenia
indication
Substance-Related Disorders
indication
Depression
indication
HIV Infections
indication
KOL
Lisa B Dixon, MD, MPH
KOL score 5
person
Stanley D. Rosenberg, PhD
KOL score —
person